

**REMARKS**

Applicants previously elected Group III drawn to claims 21-26. Applicants retain that election herein but now select for examination SEQ ID NO: 3. Claims 22, 23, and 24 read on the SEQ ID NO: 3 species. All other claims are withdrawn. Applicants reserve the right to pursue any subject matter directed to SEQ ID NO: 4 in one or more continuing applications.

Applicants relate that SEQ ID NO: 3 is a GEF-H1b peptide fragment which contains a phosphorylatable serine (Ser-810 according to the numbering of the full-length sequence). Please see Example 6 of the application. Applicants' claimed invention concerns isolated antibodies that target that peptide and its phospho-specific isoforms.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date February 6, 2007

By Beth A. Burrous

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: (202) 672-5475

Facsimile: (202) 672-5399

Beth A. Burrous, Reg. No. 35,087

Vid Mohan-Ram, Reg. No. 55,459

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check or credit card payment form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.